troglitazone has been researched along with Cardiomegaly in 5 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo." | 7.71 | Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. ( Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002) |
| "Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo." | 3.71 | Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. ( Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002) |
| " In the present study, we examined the role of PPARgamma in angiotensin II (Ang II)-induced hypertrophy of neonatal rat cardiac myocytes and in pressure overload-induced cardiac hypertrophy of mice." | 3.71 | Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. ( Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y | 1 |
| Zhang, H | 1 |
| Shao, Z | 1 |
| O'Hara, KA | 1 |
| Kopilas, MA | 1 |
| Yu, L | 1 |
| Netticadan, T | 1 |
| Anderson, HD | 1 |
| Sakai, S | 1 |
| Miyauchi, T | 1 |
| Irukayama-Tomobe, Y | 1 |
| Ogata, T | 1 |
| Goto, K | 1 |
| Yamaguchi, I | 1 |
| Yamamoto, K | 1 |
| Ohki, R | 1 |
| Lee, RT | 1 |
| Ikeda, U | 1 |
| Shimada, K | 1 |
| Asakawa, M | 1 |
| Takano, H | 1 |
| Nagai, T | 1 |
| Uozumi, H | 1 |
| Hasegawa, H | 1 |
| Kubota, N | 1 |
| Saito, T | 1 |
| Masuda, Y | 1 |
| Kadowaki, T | 1 |
| Komuro, I | 1 |
| Makino, N | 1 |
| Hirayama, H | 1 |
| Yonemochi, H | 1 |
| Yano, K | 1 |
| Abe, N | 1 |
1 trial available for troglitazone and Cardiomegaly
| Article | Year |
|---|---|
Cardiac hypertrophy in diabetes patients with and without hypertension: effects of troglitazone, a novel antidiabetic drug, on diastolic function.
Topics: Cardiomegaly; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Female; Humans; | 2001 |
4 other studies available for troglitazone and Cardiomegaly
| Article | Year |
|---|---|
Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta.
Topics: Age Factors; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Chromans; Diacylglycerol Kina | 2011 |
Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.
Topics: Analysis of Variance; Animals; Cardiomegaly; Chromans; Endothelin-1; Endothelins; Male; Natriuretic | 2002 |
Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes.
Topics: Angiotensin II; Animals; Animals, Newborn; Biological Transport; Cardiomegaly; Cells, Cultured; Chro | 2001 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Ce | 2002 |